Cover Image
Market Research Report

Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2019

Published by Global Markets Direct Product code 383707
Published Content info 227 Pages
Delivery time: 1-2 business days
Price
Back to Top
Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2019
Published: November 25, 2019 Content info: 227 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2019, provides an overview of the Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline landscape.

H1N1 Infection also called as swine flu is a new kind of flu in humans. It's caused by a contagious virus. H1N1 flu infects the breathing tubes in nose, throat, and lungs. The disease is contagious. When people who have it cough or sneeze, they spray tiny drops of the virus into the air. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache and fatigue. Treatment includes medication (antiviral drugs).

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 7, 10, 4, 44, 7 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 4, 2, 13 and 2 molecules, respectively.

Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11542IDB

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Influenza A Virus, H1N1 Subtype Infections - Overview
  • Influenza A Virus, H1N1 Subtype Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Influenza A Virus, H1N1 Subtype Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Influenza A Virus, H1N1 Subtype Infections - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Abzyme Therapeutics LLC
    • Adimmune Corp
    • Akshaya Bio Inc
    • Alla Chem LLC
    • Allergy Therapeutics Plc
    • Altimmune Inc
    • Ansun Biopharma Inc
    • Asavi Llc
    • AstraZeneca Plc
    • Beijing Minhai Biotechnology Co Ltd
    • BlueWillow Biologics Inc
    • Brandenburg Antiinfektiva GmbH
    • BunyaVax BV
    • CEL-SCI Corp
    • Changchun Bcht Biotechnology Co Ltd
    • Chicago Biosolutions Inc
    • CHO Pharma Inc
    • Cidara Therapeutics Inc
    • Cilian AG
    • Cocrystal Pharma Inc
    • Curevac AG
    • Cytocom Inc
    • Dnarx LLC
    • Emergent BioSolutions Inc
    • Ena Therapeutics Pty Ltd
    • EpiVax Inc
    • Etubics Corp
    • FluGen Inc
    • Gamma Vaccines Pty Ltd
    • Genentech Inc
    • GlaxoSmithKline Plc
    • Greffex Inc
    • i2 Pharmaceuticals Inc
    • ILiAD Biotechnologies LLC
    • Imutex Ltd
    • InvVax Inc
    • Jiangsu Kanion Pharmaceutical Co Ltd
    • Johnson & Johnson
    • Kineta Inc
    • Mayly Life Sciences
    • Medicago Inc
    • Microbiotix Inc
    • NanoViricides Inc
    • New Amsterdam Sciences Inc
    • Novavax Inc
    • OPKO Health Inc
    • PeptiDream Inc
    • Recce Ltd
    • Sanofi Pasteur SA
    • Sciogen Inc
    • Seqirus Ltd
    • Serum Institute of India Ltd
    • TechnoVax Inc
    • Tiba Biotech LLC
    • Touchlight Genetics Ltd
    • UMN Pharma Inc
    • Vaccibody AS
    • Vacthera BioTech GmbH
    • Vaxart Inc
    • Vaxxas Pty Ltd
    • Viramatix Sdn Bhd
    • Virion Biotherapeutics
    • Vironova Medical AB
    • Virvio Inc
    • Visterra Inc
    • Vivaldi Biosciences Inc
  • Influenza A Virus, H1N1 Subtype Infections - Drug Profiles
    • (oseltamivir phosphate + pimodivir hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • A-06 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Afluria Quadrivalent - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Aspidasept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AV-5027 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AV-5080 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • B-1201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CB-012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CC-42344 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CHOS-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CiFlu - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CV-7302 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DAS-181 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • diridavumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ETBX-051 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Flu-v - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fluad (Quadrivalent) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fludase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fluzone QIV HD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fusion Protein for Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gamma-Flu - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GHB-11L1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GREFLU/CAL - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • H1N1 [A/Aichi/2/68] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HB-36.6 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • infectious disease vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H1N1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/Michigan/45/2015 (H1N1)] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/Puerto Rico/8/1934 [H1N1]] (monovalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain H1N1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/ Yamagata + B/ Victoria] (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1+A/H3N2+B] (trivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1] (split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KIN-1148 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LEAPS-H1N1-DC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MBX-2546 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MC-08 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MDG-2271 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • metenkefalin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Hemagglutinin for Influenza Virus A Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Neuraminidase for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAS-911 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Nasovax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NB-1008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NP-025 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Nucleozin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NVINF-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NVINF-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotides for Influenza A Virus H1N1 Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PD-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides for Influenza Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pertussis [strain BPZE1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pimodivir hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RECCE-327 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REDEE FLU - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Neuraminidase for Influenza A Virus, H1N1 Subtype Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for RSV and Influenza A Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block M2 Channel for Influenza A Virus, H1N1 Subtype Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Neuraminidase for Influenza A Virus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PB2 for Influenza A Virus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Staphylococcus Aureus Infections and H1N1 Influenza - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TVX-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UMN-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VH-244 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VIS-410 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VMTX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VNFC-045 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VNFC-051 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VTH-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VXAA-1.1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WLBU-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Influenza A Virus, H1N1 Subtype Infections - Dormant Projects
  • Influenza A Virus, H1N1 Subtype Infections - Discontinued Products
  • Influenza A Virus, H1N1 Subtype Infections - Product Development Milestones
    • Featured News & Press Releases
      • Nov 04, 2019: Sanofi: FDA approves Fluzone High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older
      • Oct 16, 2019: Novavax begins Phase III clinical trial for influenza vaccine NanoFlu
      • Jun 27, 2019: Novavax confirms accelerated approval pathway available for licensure of Nanoflu
      • Apr 11, 2019: Altimmune to present NasoVAX Phase 2 data at the World Vaccine Congress in Washington, D.C.
      • Mar 29, 2019: hVIVO and Imutex to present at the Influenza Vaccines for the World (IVW 2019) conference at the Royal College of Physicians of Edinburgh, Scotland
      • Jan 10, 2019: HVIVO reports that the Phase Iib viral challenge Study for FLU-v (FLU-v004) achieved the primary endpoint of a statistically significant reduction in mild to moderate influenza
      • Jan 03, 2019: Novavax announces positive phase 2 NanoFlu results in older adults
      • Nov 28, 2018: Vaxart to present at World Vaccine and Immunotherapy Congress West Coast 2018
      • Nov 05, 2018: UNC researchers develop platform for universal Flu Vaccine
      • Sep 27, 2018: Novavax starts Phase ll trial of NanoFlu for seasonal influenza
      • Sep 25, 2018: AstraZeneca ships FLUMIST QUADRIVALENT vaccine in the US for 2018-2019 flu season
      • Sep 17, 2018: Virion Appoints Vanessa King as President & CEO and Isabel Najera as CSO
      • Sep 04, 2018: Altimmune announces additional positive data from its phase 2a study of NasoVAX Intranasal Influenza Vaccine
      • Jun 18, 2018: hVIVO reports positive results from the Phase Iib field study of FLU-v (FLU-v 003) representing a significant advance in the management of influenza disease
      • Apr 04, 2018: Vivaldi Biosciences Presents Data at the World Vaccine Congress Demonstrating Potential of deltaFLU as Universal Influenza Vaccine
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Table 6: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 7: Products under Development by Companies, H2 2019
  • Table 8: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 9: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 10: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Table 11: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Table 12: Products under Development by Universities/Institutes, H2 2019
  • Table 13: Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
  • Table 14: Number of Products by Stage and Target, H2 2019
  • Table 15: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 16: Number of Products by Stage and Route of Administration, H2 2019
  • Table 17: Number of Products by Stage and Molecule Type, H2 2019
  • Table 18: Influenza A Virus, H1N1 Subtype Infections - Pipeline by AbbVie Inc, H2 2019
  • Table 19: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Abzyme Therapeutics LLC, H2 2019
  • Table 20: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Adimmune Corp, H2 2019
  • Table 21: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Akshaya Bio Inc, H2 2019
  • Table 22: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Alla Chem LLC, H2 2019
  • Table 23: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Allergy Therapeutics Plc, H2 2019
  • Table 24: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Altimmune Inc, H2 2019
  • Table 25: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Ansun Biopharma Inc, H2 2019
  • Table 26: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Asavi Llc, H2 2019
  • Table 27: Influenza A Virus, H1N1 Subtype Infections - Pipeline by AstraZeneca Plc, H2 2019
  • Table 28: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2019
  • Table 29: Influenza A Virus, H1N1 Subtype Infections - Pipeline by BlueWillow Biologics Inc, H2 2019
  • Table 30: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Brandenburg Antiinfektiva GmbH, H2 2019
  • Table 31: Influenza A Virus, H1N1 Subtype Infections - Pipeline by BunyaVax BV, H2 2019
  • Table 32: Influenza A Virus, H1N1 Subtype Infections - Pipeline by CEL-SCI Corp, H2 2019
  • Table 33: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Changchun Bcht Biotechnology Co Ltd, H2 2019
  • Table 34: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Chicago Biosolutions Inc, H2 2019
  • Table 35: Influenza A Virus, H1N1 Subtype Infections - Pipeline by CHO Pharma Inc, H2 2019
  • Table 36: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cidara Therapeutics Inc, H2 2019
  • Table 37: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cilian AG, H2 2019
  • Table 38: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cocrystal Pharma Inc, H2 2019
  • Table 39: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Curevac AG, H2 2019
  • Table 40: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cytocom Inc, H2 2019
  • Table 41: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Dnarx LLC, H2 2019
  • Table 42: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Emergent BioSolutions Inc, H2 2019
  • Table 43: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Ena Therapeutics Pty Ltd, H2 2019
  • Table 44: Influenza A Virus, H1N1 Subtype Infections - Pipeline by EpiVax Inc, H2 2019
  • Table 45: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Etubics Corp, H2 2019
  • Table 46: Influenza A Virus, H1N1 Subtype Infections - Pipeline by FluGen Inc, H2 2019
  • Table 47: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Gamma Vaccines Pty Ltd, H2 2019
  • Table 48: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Genentech Inc, H2 2019
  • Table 49: Influenza A Virus, H1N1 Subtype Infections - Pipeline by GlaxoSmithKline Plc, H2 2019
  • Table 50: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Greffex Inc, H2 2019
  • Table 51: Influenza A Virus, H1N1 Subtype Infections - Pipeline by i2 Pharmaceuticals Inc, H2 2019
  • Table 52: Influenza A Virus, H1N1 Subtype Infections - Pipeline by ILiAD Biotechnologies LLC, H2 2019
  • Table 53: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Imutex Ltd, H2 2019
  • Table 54: Influenza A Virus, H1N1 Subtype Infections - Pipeline by InvVax Inc, H2 2019
  • Table 55: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2019
  • Table 56: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Johnson & Johnson, H2 2019
  • Table 57: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Kineta Inc, H2 2019
  • Table 58: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Mayly Life Sciences, H2 2019
  • Table 59: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Medicago Inc, H2 2019
  • Table 60: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Microbiotix Inc, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Figure 4: Number of Products by Top 10 Targets, H2 2019
  • Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
  • Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
  • Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top